Prucalopride succinateProduct ingredient for Prucalopride

Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties.² The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies.⁵ Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009,¹ in Canada on December 7, 2011 and by the FDA on December 17, 2018.⁷